AVLN Stock Forecast: Avalyn Pharma, Inc. Price Predictions for 2026-2027
The 4 Wall Street analysts covering Avalyn Pharma, Inc. hold a median 12-month price target of $53 — +84.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
AVLN stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Avalyn Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (42): Smaller than most of the companies we track.
Volatility (3): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own Avalyn Pharma, Inc. — and when they’d sell — is the membership.
AVLN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on AVLN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +84.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 May 2026 | Evercore ISI Group | Initiates | Outperform | $51 |
| 26 May 2026 | Guggenheim | Initiates | Buy | $80 |
| 26 May 2026 | Morgan Stanley | Initiates | Overweight | $53 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
AVLN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Avalyn Pharma, Inc. (AVLN) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −14.1×
- Price / sales
- —
- Price / book
- −4.6×
- EV / EBITDA
- −15.4×
Cheaper than 95% of US stocks
Cheaper than 96% of US stocks
Cheaper than 88% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- 35.7%
- Return on assets
- −57.2%
- Dividend yield
- —
Higher than 90% of US stocks
Higher than 6% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
AVLN vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AVLN appears on the weeks it earns a place.
Frequently asked questions about AVLN stock
What is the AVLN stock price forecast for 2026-2027?
The 4 Wall Street analysts covering Avalyn Pharma, Inc. have a median 12-month price target of $53, with estimates ranging from $51 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is AVLN stock a buy right now?
Of the 4 analysts covering Avalyn Pharma, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Avalyn Pharma, Inc. 1 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank AVLN?
As at 1 Aug 2026, Avalyn Pharma, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (42 of 100).
Will AVLN stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts implies +84.2% from the last close, and Ticker Nerd's factor model ranks Avalyn Pharma, Inc. 1 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the AVLN stock forecast for 2030?
No analyst covering Avalyn Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVLN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $51 to $80 over the next 12 months.
What does Avalyn Pharma, Inc. do?
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company developing inhaled therapies for rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.
About Avalyn Pharma, Inc.
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company developing inhaled therapies for rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. Its pipeline features optimized inhaled formulations of established antifibrotic medicines, such as AP01, an inhaled version of pirfenidone for progressive pulmonary fibrosis, and AP02, an inhaled formulation of nintedanib for idiopathic pulmonary fibrosis. This nebulization approach aims to deliver medication directly to the lung tissue, potentially improving efficacy while reducing the significant side effects and tolerability issues associated with current oral therapies that often limit patient compliance. Avalyn Pharma Inc. focuses on addressing the unmet needs in treating these progressive conditions by enhancing local drug delivery and minimizing systemic exposure. Founded in 2011 and headquartered in Boston, Massachusetts, the company operates in the biopharmaceutical sector targeting serious rare lung disorders.
CEO Ms. Lyn Baranowski · 50 employees · United States · https://www.avalynpharma.com